Skip to main content Skip to search Skip to main navigation

EC: New Entries in the MDCG Borderline Manual

The Medical Device Coordination Group (MDCG) has updated its manual on the classification of products that are on the borderlines between medtech and other regulatory categories (Version 4).

The following newly added cases illustrate current regulatory decisions on qualification and classification:

  • Red blood cell additive solutions containing adenine
    Medical Device, Class III
    Adenine exerts metabolic/pharmacological effects on RBCs; therefore, the solution is classified as part of a Class III device.
  • Dual-action cream with menthol and capsaicin
    Not a medical device
    Principal mode of action is pharmacological (via receptor activity); classified as a medicinal product.
  • Lactose vaginal tablets
    Not a medical device
    Mode of action is metabolic, based on lactic acid bacteria metabolizing lactose into lactic acid.
  • Microabrasion dental stain removers (tooth whitening)
    Not a medical device
    Purely cosmetic purpose (aesthetic improvement), no proven medical benefit.
  • Medical examination table covers
    Medical device
    Intended to prevent disease transmission (infection prevention), thus meeting the definition of a medical device.
  • Mobile sterile air system
    Not a medical device
    Controls the environment (air purification/laminar flow), without direct action in or on the human body.

The updates highlight the strict distinction between medical purpose and cosmetic, pharmacological, or purely environmental functions. Manufacturers must provide robust scientific evidence of the principal mode of action to ensure correct regulatory qualification.


Source:

EC: Manual on borderline and classification for medical devices under Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

The EMA has published a new Q&A paper on technical and organisational measures to prevent microbial contamination of non-sterile medicinal products.
Read more
When APS Fail and First Air is at Risk

When APS Fail and First Air is at Risk

At the PDA Good Aseptic Manufacturing Conference 2026, Alberto Gonzales (Takeda) discussed challenges and practical solutions related to aseptic process simulations (APS). Anna Campanella (Takeda) and Hussein Bachir (Franz Ziel) explored how first air protection in aseptic processing can be compromised by equipment design, glove interventions, and operator activities.
Read more
Why is import authorisation necessary for medicinal products entering the EU?

Why is import authorisation necessary for medicinal products entering the EU?

Read more
FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
EMA: Revised Q&A MRA EU-USA

EMA: Revised Q&A MRA EU-USA

The EMA has updated its Questions and Answers on the EU-US Mutual Recognition Agreement (MRA). The update follows the completion of the FDA's assessment of all EU authorities responsible for GMP inspections of veterinary medicinal products on 29 May 2026.
Read more
WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO published a draft consultation document on regulatory oversight of disposal of medical products throughout the lifecycle.
Read more
Previous
Next